Disease/Infection News

RSS

Effective compound against antibiotic-resistant biofilms

Researchers at North Carolina State University have found a chemical compound that, when used in conjunction with conventional antibiotics, is effective in destroying biofilms produced by antibiotic-resistant strains of bacteria such as the Staphylococcus strain MRSA and Acinetobacter. The compound also re-sentsitizes those bacteria to antibiotics.

9 Apr 2010

Inovio Biomedical receives $2.8M grant to develop DNA vaccine for HCV

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that the company and its collaborators from Drexel University, Cheyney University, and the University of Pennsylvania have received a $2.8 million grant to develop a DNA vaccine to treat hepatitis C virus.

9 Apr 2010

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

The efficacy of interferon (IFN) therapy depends on the hepatitis C virus (HCV) genotype, pretreatment viral load and early viral kinetics. Thus, IFN therapy must be individualized and optimized according to the virological and clinical status of each patient.

9 Apr 2010

FDA updates website with information about triclosan

The U.S. Food and Drug Administration today updated its website www.fda.gov with information about triclosan, a common ingredient added to many consumer products to reduce or prevent bacterial contamination. It may be found in antibacterial soaps and body washes, toothpastes and some cosmetics—products regulated by the FDA.

9 Apr 2010

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

ChemoCentryx, Inc., today announced that it has identified a novel drug candidate targeting the chemoattractant receptor known as ChemR23. This investigational new drug, designated CCX832, is an orally-administered small molecule antagonist of ChemR23, an important player in inflammatory disease.

9 Apr 2010

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Using T cells primed for the infectious disease toxoplasmosis, Whitehead Institute researchers have created novel mouse models of the immune system that more accurately reflect how immune cells actually respond to pathogens in their presence.

9 Apr 2010

Combination telaprevir treatment beneficial for retreatment of hepatitis C

A study co-authored by a Saint Louis University researcher found telaprevir, a protease inhibitor, combined with standard hepatitis C treatment, cures a significantly higher number of difficult-to-treat patients than standard treatment alone. The findings were published in the April issue of the New England Journal of Medicine.

9 Apr 2010

Opinions: Preparing for next flu outbreak; Elections in Zimbabwe; U.S. response to Haiti

Now that concerns about swine flu have eased, "[o]ur fear is that the public and officials will get blase about the next flu outbreak," according to a New York Times editorial. "Efforts to rush vaccine into production did not go well. This dry run should lead health officials to push the vaccine makers even harder to adopt new technologies that can turn out vaccine more quickly.

9 Apr 2010

Pfizer to expand clinical trials in Asia, work on development of antibiotics for drug-resistant TB

The pharmaceutical company Pfizer said on Wednesday that it plans to increase the number of clinical trials it's conducting in Singapore by 10 percent as part of an effort "to design drugs for diseases prevalent in the region," Reuters reports.

9 Apr 2010

12 infected with Hepatitis C by a doctor at clinic in Victoria

Hepatitis C is a vial infection that is spread much like HIV with shared needles, blood or body fluids. The Victorian Police has been brought in to investigate a cluster of 12 hepatitis C positive cases who attended a late-term abortion clinic in Melbourne.

9 Apr 2010

Superbugs on the decline in Scottish hospitals

The number of cases of hospital infections is on the decline in Scotland. Clostridium difficile, the hospital super bug which brings down a number of patients each year have halved in the last year. In the last 3 months of last year the patients over 65 years reported 672 cases of Clostridium difficile. This is a 48% decline from the 1,299 cases reported in the last three months of 2008.

9 Apr 2010

Miami Medicare case spotlights federal probes into HIV therapy fraud

A new Miami Medicare fraud case spotlights federal investigations of massive scams using HIV therapies.

9 Apr 2010

LA BioMed to receive $9.7M federal grant for construction of new Chronic Disease Clinical Research Center

With a goal of creating jobs and enhancing chronic disease studies, the federal government is awarding a $9.7 million grant of stimulus funds to the Los Angeles Biomedical Research Institute (LA BioMed) for the construction of a new Chronic Disease Clinical Research Center on its campus, David I. Meyer, PhD, the institute's president and CEO, announced today.

9 Apr 2010

Ribavirin Biopartners 200mg film-coated tablets granted EU marketing approval

Biopartners GmbH has announced that it has received EU marketing authorization from the European Commission for Ribavirin Biopartners 200mg film-coated tablets. The product is intended for the treatment of chronic hepatitis C infection as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b.

9 Apr 2010

Cubist Pharmaceuticals initiates dosing in Phase 2 trial with CB-183,315 for diarrhea due to CDAD

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company, today announced the enrollment and dosing of the first subject in its Phase 2 trial with CB-183,315, an antibacterial drug candidate intended to treat patients with a severe and sometimes life-threatening diarrhea caused by Clostridium difficile known as C. difficile-associated diarrhea, or CDAD. The trial is expected to enroll more than 200 subjects at 28 sites in the United States and Canada.

8 Apr 2010

Phase 1 SAD study of PSI-938 for HCV initiated

Pharmasset, Inc. announced today that dosing has initiated in a phase 1, single ascending dose study in healthy volunteers with PSI-938, a third generation purine nucleotide analog polymerase inhibitor of hepatitis C virus. Pharmasset recently filed an Investigational New Drug Application with the Food and Drug Administration.

8 Apr 2010

Allergy flare-ups due to indoor allergens

Spring is here and allergy flare-ups are often attributed to the allergens outside your front door. However, did you know that the same allergens are found on surfaces inside 75 million homes across America? According to the Centers for Disease Control and Prevention (CDC), some of the most common indoor allergens include dust mites, mold and household pets.

8 Apr 2010

Pittsburgh managing diabetes more cost effectively than other states

Pittsburgh is treating diabetes more cost effectively than the rest of the state and nation, and its efforts to help people better manage their disease are paying dividends. Still, a gap exists between the region and the nation's top performers, according to the third annual Pittsburgh Business Group on Health Type 2 Diabetes Report.

8 Apr 2010

Hospital TV remotes are potential reservoir of bacteria

According to RID (Committee to Reduce Infection Deaths) over thirty billion dollars is spent each year in the US on hospital-acquired infections. (Infections caught while hospitalized). These very preventable infections cost an additional $15,000.00 on average per patient infected and kill more people in this country than AIDS, breast cancer and car accidents combined.

8 Apr 2010

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

In a clinical trial known as PROVE 3 published in this week's New England Journal of Medicine, treatment with telaprevir-based regimens significantly increased rates of sustained viral response (SVR) in patients with genotype 1 hepatitis C virus (HCV) infection who did not achieve SVR with at least one prior course of pegylated-interferon and ribavirin therapy.

8 Apr 2010

Disease/Infection News

Effective compound against antibiotic-resistant biofilms

Inovio Biomedical receives $2.8M grant to develop DNA vaccine for HCV

IFN therapy for chronic hepatitis C must be individualized and optimized for efficacy

FDA updates website with information about triclosan

ChemoCentryx identifies novel drug candidate targeting ChemR23 chemoattractant receptor

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Combination telaprevir treatment beneficial for retreatment of hepatitis C

Opinions: Preparing for next flu outbreak; Elections in Zimbabwe; U.S. response to Haiti

Pfizer to expand clinical trials in Asia, work on development of antibiotics for drug-resistant TB

12 infected with Hepatitis C by a doctor at clinic in Victoria

Superbugs on the decline in Scottish hospitals

Miami Medicare case spotlights federal probes into HIV therapy fraud

LA BioMed to receive $9.7M federal grant for construction of new Chronic Disease Clinical Research Center

Ribavirin Biopartners 200mg film-coated tablets granted EU marketing approval

Cubist Pharmaceuticals initiates dosing in Phase 2 trial with CB-183,315 for diarrhea due to CDAD

Phase 1 SAD study of PSI-938 for HCV initiated

Allergy flare-ups due to indoor allergens

Pittsburgh managing diabetes more cost effectively than other states

Hospital TV remotes are potential reservoir of bacteria

Telaprevir-based regimens increase rates of SVR in patients with genotype 1 HCV infection

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News